An experimental treatment for mesothelioma is showing striking results in early research.
In June 2025, MVdeltaC received orphan drug designation from the U.S. Food and Drug Administration (FDA) — a special status that supports the development of treatments for rare diseases like mesothelioma.
Now, newly published preclinical data shows that MVdeltaC eliminated tumors in most treated animals and triggered a powerful cancer-fighting immune response.
While the treatment is not yet available to patients, researchers say the results are strong enough to support moving into human clinical trials.
How MVdeltaC Works to Fight Mesothelioma
MVdeltaC is a modified version of the measles vaccine virus, allowing researchers to build off the established safety of an existing medication. Scientists made the virus easier to find by the immune system, stimulating a more powerful immune attack on mesothelioma cells.
This virotherapy for mesothelioma is injected directly into tumors. It targets mesothelioma cells by attaching to a protein called CD46, which is found in high amounts on these cancer cells.
Once inside, the virus multiplies and causes the cancer cell to burst. At the same time, it sends strong signals that alert the immune system to attack any remaining mesothelioma cells.
Get our Free Mesothelioma Guide to learn more about the latest treatment options, explore clinical trials, and find support resources for you and your family.
What the Latest Research Shows
Researchers tested MVdeltaC in more than 40 different cancer cell types, including multiple mesothelioma samples.
Lab Study Results
In controlled lab tests, scientists compared MVdeltaC to the standard measles vaccine virus. They closely measured how quickly cancer cells were destroyed and how strongly the immune system was activated.
The results showed:
- The modified virus killed mesothelioma cells faster and more completely than the standard measles virus.
- Infected tumor cells released strong immune “alarm signals.”
- Some of these signals increased by up to 10,000 times compared to the unmodified virus.
By dramatically increasing these alarm signals, MVdeltaC may help the immune system recognize previously “invisible” tumors and attack them. Importantly, healthy cells were mostly resistant to infection, potentially leading to fewer side effects compared to traditional treatments.
Animal Study Results
Before a new mesothelioma treatment can be tested in people, it must show promise in laboratory and animal studies. In the case of MVdeltaC, the results in animal models were especially encouraging and gave scientists strong reason to continue testing this virotherapy.
In mice with healthy immune systems:
- 3 injections eliminated tumors in about 70% of the animals
- 5 injections increased complete tumor elimination to 90%
Animals that were cured later rejected new tumors, which suggests long-lasting immune protection.
In mice implanted with human mesothelioma tumors:
- A single low-dose injection significantly reduced tumor mass within 2 weeks.
- The therapy also worked in tumors taken directly from mesothelioma patients and those grown in lab models.
Researchers discovered that the treatment’s success depended on the immune system. When key immune cells were removed, the therapy stopped working. This suggests MVdeltaC does more than just destroy tumors — it helps train the immune system to keep fighting.
Why This Matters and What Happens Next
Mesothelioma is an aggressive cancer that is difficult to treat. Even when surgery, chemotherapy, or immunotherapy works at first, tumors can return. Because of this, researchers continue searching for emerging treatments that work in different ways.
This approach stands out because it may:
- Directly destroy tumors
- Strengthen the body’s natural defenses
- Help prevent mesothelioma recurrence
- Potentially work alongside immunotherapy
The next step is human testing. MVdeltaC is expected to move into phase I clinical trials. During this stage, researchers study safety, determine the proper dose, and look for early signs that the treatment works in patients.
Get Help Exploring Mesothelioma Treatment and Clinical Trials
At Mesothelioma Hope, our Patient Advocates are here to help you understand your diagnosis, explore treatment options, and learn whether a clinical trial may be right for you.
We can also help match you with mesothelioma clinical trials based on your diagnosis, cancer stage, and treatment history. Our team helps patients find leading specialists and cancer centers across the country.
There’s no cost to speak with us, and we have registered nurses on staff who are ready to answer your questions and provide the information you need to make the best decisions for your family.
Call (866) 608-8933 or reach out online today. We’re here to help you navigate your next steps with support and compassion.
